ADT Plus Docetaxel Chemo May Increase Survival in Metastatic Prostate Cancer
Adding chemotherapy to hormone therapy added 14 months to patients’ lives in study.
Adding chemotherapy to hormone therapy added 14 months to patients’ lives in study.
No improvement in quality of life, even for patients with good baseline performance status.
Review of 79 studies indicates only low-quality evidence for other conditions
Androgen receptor splice variant 7 (AR-V7) detection may serve as treatment biomarker in castration-resistant prostate cancer (CRPC).
Research raises concern about the simultaneous use of chemotherapy and fish oil.
Patients aged 70 and older are less likely than younger patients to receive post-cystectomy treatment, despite survival benefit
These include patients with positive lymph nodes and surgical margins after cystectomy.
Detection of AR-V7 in circulating tumor cells linked to enzalutamide and abiraterone resistance.
Giving men a single dose of chemotherapy along with radiotherapy may help improve the effectiveness of treatment.